Pinos Elisabet de los - Nov 2, 2021 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Julie Feder, as Attorney-in-Fact
Stock symbol
AURA
Transactions as of
Nov 2, 2021
Transactions value $
$0
Form type
4
Date filed
11/2/2021, 04:13 PM
Previous filing
Oct 28, 2021
Next filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Conversion of derivative security $0 +4.55K +3.59% $0.00 131K Nov 2, 2021 By EdIP Revocable Trust F1, F2
holding AURA Common Stock 74.4K Nov 2, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Series A-1 Preferred Stock Conversion of derivative security -3.04K -100% 0 Nov 2, 2021 Common Stock 3.04K By EdIP Revocable Trust F1, F2
transaction AURA Series A-2 Preferred Stock Conversion of derivative security -1.51K -100% 0 Nov 2, 2021 Common Stock 1.51K By EdIP Revocable Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.
F2 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Remarks:

President and Chief Executive Officer